Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption.

Wolenski FS, Xia CQ, Ma B, Han TH, Shyu WC, Balani SK.

Eur J Drug Metab Pharmacokinet. 2018 Jun;43(3):347-354. doi: 10.1007/s13318-017-0455-5.

PMID:
29264831
2.

Preface.

Balani SK.

Drug Metab Lett. 2017 Nov 17;11(1):2. doi: 10.2174/187231281101171117161507. No abstract available.

PMID:
29197321
3.

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control.

Hariparsad N, Ramsden D, Palamanda J, Dekeyser JG, Fahmi OA, Kenny JR, Einolf H, Mohutsky M, Pardon M, Siu YA, Chen L, Sinz M, Jones B, Walsky R, Dallas S, Balani SK, Zhang G, Buckley D, Tweedie D.

Drug Metab Dispos. 2017 Oct;45(10):1049-1059. doi: 10.1124/dmd.116.074567. Epub 2017 Jun 23.

PMID:
28646080
4.

PREFACE.

Balani SK.

Drug Metab Lett. 2016;10(1):2. No abstract available.

PMID:
27331219
5.

Preface.

Balani SK.

Drug Metab Lett. 2015;9(1):2. No abstract available.

PMID:
26322351
6.

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors.

Sells TB, Chau R, Ecsedy JA, Gershman RE, Hoar K, Huck J, Janowick DA, Kadambi VJ, LeRoy PJ, Stirling M, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Balani SK, Bolen JB, Manfredi MG, Claiborne CF.

ACS Med Chem Lett. 2015 Apr 22;6(6):630-4. doi: 10.1021/ml500409n. eCollection 2015 Jun 11.

7.

Metabolism, Excretion and Pharmacokinetics of MLN3897, a CCR1 Antagonist, in Humans.

Pusalkar S, Plesescu M, Milton M, Balani SK, Chowdhury S, Prakash S.

Drug Metab Lett. 2016;10(1):22-37.

PMID:
26031460
8.

Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group.

Yu H, Balani SK, Chen W, Cui D, He L, Humphreys WG, Mao J, Lai WG, Lee AJ, Lim HK, MacLauchlin C, Prakash C, Surapaneni S, Tse S, Upthagrove A, Walsky RL, Wen B, Zeng Z.

Drug Metab Dispos. 2015 Apr;43(4):620-30. doi: 10.1124/dmd.114.059345. Epub 2015 Feb 5.

PMID:
25655830
9.

Editorial.

Balani SK.

Drug Metab Lett. 2014;8(1):1. No abstract available.

PMID:
25313019
10.

Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).

Yang JJ, Li Y, Chakravarty A, Lu C, Xia CQ, Chen S, Pusalkar S, Zhang M, Ecsedy J, Manfredi MG, Wu JT, Shyu WC, Balani SK.

Drug Metab Lett. 2014 Jul;7(2):96-104.

PMID:
24484538
11.

Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.

Palani S, Patel M, Huck J, Zhang M, Balani SK, Yang J, Chen S, Mettetal J, Manfredi M, Shyu WC, Ecsedy JA, Chakravarty A.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1255-64. doi: 10.1007/s00280-013-2305-8. Epub 2013 Oct 8.

PMID:
24101146
12.

Mutagenicity and tumorigenicity of the four enantiopure bay-region 3,4-diol-1,2-epoxide isomers of dibenz[a,h]anthracene.

Chang RL, Wood AW, Huang MT, Xie JG, Cui XX, Reuhl KR, Boyd DR, Lin Y, Shih WJ, Balani SK, Yagi H, Jerina DM, Conney AH.

Carcinogenesis. 2013 Sep;34(9):2184-91. doi: 10.1093/carcin/bgt164. Epub 2013 May 13.

13.

A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors.

Li P, Lu C, Balani SK, Gan LS.

Drug Metab Dispos. 2011 Jun;39(6):1054-7. doi: 10.1124/dmd.111.038208. Epub 2011 Mar 10. Erratum in: Drug Metab Dispos. 2011 Sep;39(9):1777.

PMID:
21393461
14.

P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.

Yang JJ, Milton MN, Yu S, Liao M, Liu N, Wu JT, Gan L, Balani SK, Lee FW, Prakash S, Xia CQ.

Drug Metab Lett. 2010 Dec;4(4):201-12.

PMID:
20670210
15.

Inhibition of hepatic organic anion-transporting polypeptide by RNA interference in sandwich-cultured human hepatocytes: an in vitro model to assess transporter-mediated drug-drug interactions.

Liao M, Raczynski AR, Chen M, Chuang BC, Zhu Q, Shipman R, Morrison J, Lee D, Lee FW, Balani SK, Xia CQ.

Drug Metab Dispos. 2010 Sep;38(9):1612-22. doi: 10.1124/dmd.110.032995. Epub 2010 Jun 1.

PMID:
20516252
16.

Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.

Lu C, Balani SK, Qian MG, Prakash SR, Ducray PS, von Moltke LL.

J Pharmacol Exp Ther. 2010 Feb;332(2):562-8. doi: 10.1124/jpet.109.161893. Epub 2009 Nov 4.

PMID:
19889796
17.

Proposed new addition to 3Rs for ethical and humane use of rats in pharmacokinetic studies--'Recycle'.

Balani SK, Lu C, Cardoza K, Berg C, Zhang J, Lee FW.

Drug Metab Lett. 2008 Aug;2(3):193-7.

PMID:
19356093
18.

Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.

Lu C, Hatsis P, Berg C, Lee FW, Balani SK.

Drug Metab Dispos. 2008 Jul;36(7):1255-60. doi: 10.1124/dmd.107.018796. Epub 2008 Apr 1.

PMID:
18381489
19.

Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole.

Lu C, Berg C, Prakash SR, Lee FW, Balani SK.

Drug Metab Dispos. 2008 Jul;36(7):1261-6. doi: 10.1124/dmd.107.019000. Epub 2008 Apr 1.

PMID:
18381488
20.

An indirect screen for brain uptake of 1,2-diarylethane melanocortin 4 receptor antagonists in rats.

Yin W, Gan LS, Wu JT, Balani SK, Yang H, Lee FW.

Drug Metab Lett. 2007 Aug;1(3):195-8.

PMID:
19356043
21.

Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction.

Li P, Callery PS, Gan LS, Balani SK.

Drug Metab Dispos. 2007 Jul;35(7):1203-8. Epub 2007 Apr 23.

PMID:
17452418
22.

Esterase inhibition attribute of grapefruit juice leading to a new drug interaction.

Li P, Callery PS, Gan LS, Balani SK.

Drug Metab Dispos. 2007 Jul;35(7):1023-31. Epub 2007 Mar 28.

PMID:
17392396
23.

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.

Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, Ray ET, Sells TB, Stringer B, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Bolen JB, Claiborne CF.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4106-11. Epub 2007 Feb 23.

24.

A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.

Lu C, Miwa GT, Prakash SR, Gan LS, Balani SK.

Drug Metab Dispos. 2007 Jan;35(1):79-85. Epub 2006 Oct 4.

PMID:
17020957
25.

Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes.

Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, Gan LS.

Drug Metab Dispos. 2006 Sep;34(9):1600-5. Epub 2006 Jun 21.

PMID:
16790553
26.

Identification and characterization of 4-aryl-3,4-dihydropyrimidin-2(1H)-ones as inhibitors of the fatty acid transporter FATP4.

Blackburn C, Guan B, Brown J, Cullis C, Condon SM, Jenkins TJ, Peluso S, Ye Y, Gimeno RE, Punreddy S, Sun Y, Wu H, Hubbard B, Kaushik V, Tummino P, Sanchetti P, Yu Sun D, Daniels T, Tozzo E, Balani SK, Raman P.

Bioorg Med Chem Lett. 2006 Jul 1;16(13):3504-9. Epub 2006 Apr 27.

PMID:
16644217
27.

Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.

Balani SK, Nagaraja NV, Qian MG, Costa AO, Daniels JS, Yang H, Shimoga PR, Wu JT, Gan LS, Lee FW, Miwa GT.

Drug Metab Dispos. 2006 Mar;34(3):384-8. Epub 2005 Dec 2.

PMID:
16326814
28.

Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection.

Balani SK, Miwa GT, Gan LS, Wu JT, Lee FW.

Curr Top Med Chem. 2005;5(11):1033-8. Review.

PMID:
16181128
29.

Testing paradigm for prediction of development-limiting barriers and human drug toxicity.

Sasseville VG, Lane JH, Kadambi VJ, Bouchard P, Lee FW, Balani SK, Miwa GT, Smith PF, Alden CL.

Chem Biol Interact. 2004 Nov 1;150(1):9-25. Review.

PMID:
15522258
30.

Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling.

Balani SK, Li P, Nguyen J, Cardoza K, Zeng H, Mu DX, Wu JT, Gan LS, Lee FW.

Drug Metab Dispos. 2004 Oct;32(10):1092-5. Epub 2004 Jun 24.

PMID:
15217988
31.

Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys.

Sandhu P, Xu X, Bondiskey PJ, Balani SK, Morris ML, Tang YS, Miller AR, Pearson PG.

Antimicrob Agents Chemother. 2004 Apr;48(4):1272-80.

32.

Interaction of ritonavir on tissue distribution of a [(14)c]L-valinamide, a potent human immunodeficiency virus-1 protease inhibitor, in rats using quantitative whole-body autoradiography.

Solon EG, Balani SK, Luo G, Yang TJ, Haines PJ, Wang L, Demond T, Diamond S, Christ DD, Gan LS, Lee FW.

Drug Metab Dispos. 2002 Nov;30(11):1164-9.

PMID:
12386120
33.

Whole-body autoradiography in drug discovery.

Solon EG, Balani SK, Lee FW.

Curr Drug Metab. 2002 Oct;3(5):451-62. Review.

PMID:
12369892
34.

Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys.

Balani SK, Zhu T, Yang TJ, Liu Z, He B, Lee FW.

Drug Metab Dispos. 2002 Oct;30(10):1059-62.

PMID:
12228180
35.

Tumorigenicity of racemic and optically pure bay region diol epoxides and other derivatives of the nitrogen heterocycle dibenz[a,h]acridine on mouse skin.

Kumar S, Chang RL, Wood AW, Xie JG, Huang MT, Cui XX, Kole PL, Sikka HC, Balani SK, Conney AH, Jerina DM.

Carcinogenesis. 2001 Jun;22(6):951-5.

PMID:
11375904
36.

Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine.

Balani SK, Xu X, Arison BH, Silva MV, Gries A, DeLuna FA, Cui D, Kari PH, Ly T, Hop CE, Singh R, Wallace MA, Dean DC, Lin JH, Pearson PG, Baillie TA.

Drug Metab Dispos. 2000 Nov;28(11):1274-8.

PMID:
11038152
37.

In vitro and in vivo studies on the metabolism of tirofiban.

Vickers S, Theoharides AD, Arison B, Balani SK, Cui D, Duncan CA, Ellis JD, Gorham LM, Polsky SL, Prueksaritanont T, Ramjit HG, Slaughter DE, Vyas KP.

Drug Metab Dispos. 1999 Nov;27(11):1360-6.

PMID:
10534322
38.

Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys.

Balani SK, Kauffman LR, deLuna FA, Lin JH.

Drug Metab Dispos. 1999 Jan;27(1):41-5.

PMID:
9884307
39.

Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.

Balani SK, Xu X, Pratha V, Koss MA, Amin RD, Dufresne C, Miller RR, Arison BH, Doss GA, Chiba M, Freeman A, Holland SD, Schwartz JI, Lasseter KC, Gertz BJ, Isenberg JI, Rogers JD, Lin JH, Baillie TA.

Drug Metab Dispos. 1997 Nov;25(11):1282-7.

PMID:
9351905
40.

Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans.

Chiba M, Xu X, Nishime JA, Balani SK, Lin JH.

Drug Metab Dispos. 1997 Sep;25(9):1022-31.

PMID:
9311616
41.

Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.

Balani SK, Woolf EJ, Hoagland VL, Sturgill MG, Deutsch PJ, Yeh KC, Lin JH.

Drug Metab Dispos. 1996 Dec;24(12):1389-94.

PMID:
8971147
42.

Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.

Lin JH, Chiba M, Balani SK, Chen IW, Kwei GY, Vastag KJ, Nishime JA.

Drug Metab Dispos. 1996 Oct;24(10):1111-20.

PMID:
8894513
43.
44.

Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.

Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH.

Drug Metab Dispos. 1996 Mar;24(3):307-14.

PMID:
8820421
45.

Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.

Prueksaritanont T, Balani SK, Dwyer LM, Ellis JD, Kauffman LR, Varga SL, Pitzenberger SM, Theoharides AD.

Drug Metab Dispos. 1995 Jul;23(7):688-95.

PMID:
7587955
46.

Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.

Balani SK, Arison BH, Mathai L, Kauffman LR, Miller RR, Stearns RA, Chen IW, Lin JH.

Drug Metab Dispos. 1995 Feb;23(2):266-70.

PMID:
7736923
47.

Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors.

Balani SK, Pitzenberger SM, Schwartz MS, Ramjit HG, Thompson WJ.

Drug Metab Dispos. 1995 Feb;23(2):185-9.

PMID:
7736909
49.

Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2 (1H)-one (L-696,229), an HIV-1 reverse transcriptase inhibitor, by rat liver slices and in humans.

Balani SK, Kauffman LR, Arison BH, Olah TV, Goldman ME, Varga SL, O'Brien JA, Ramjit HG, Rooney CS, Hoffman JM, et al.

Drug Metab Dispos. 1994 Mar-Apr;22(2):200-5.

PMID:
7516852
50.

Bacterial and mammalian cell mutagenicity of four optically active bay-region 10,11-diol-8,9-epoxides of the nitrogen heterocycle dibenz[a,h]acridine.

Chang RL, Battista S, Wong CQ, Kumar S, Kole PL, Sikka HC, Balani SK, Jerina DM, Conney AH, Wood AW.

Carcinogenesis. 1993 Nov;14(11):2233-7.

PMID:
8242848

Supplemental Content

Loading ...
Support Center